Orchestra BioMed to Host Business Update Call on November 12, 2025
Orchestra BioMed (Nasdaq: OBIO) will host a business update call on Wednesday, November 12, 2025 at 8:00 AM ET. The company said the call will cover recent clinical, strategic and financing developments, including an additional strategic investment and collaboration expansion with Medtronic, a new strategic capital relationship with Ligand, a right of first refusal agreement with Terumo, acceleration of enrollment in the BACKBEAT pivotal study of AVIM Therapy, and initiation of patient enrollment in the Virtue SAB US pivotal IDE coronary trial.
Conference details: Toll Free 877-407-9039; International 201-689-8470; Conference ID 13756518; webcast available at https://viavid.webcasts.com/starthere.jsp?ei=1738644&tp_key=c80bc7995c.
Orchestra BioMed (Nasdaq: OBIO) terrà una chiamata di aggiornamento aziendale mercoledì 12 novembre 2025 alle 8:00 ET. L'azienda ha detto che la chiamata riguarderà gli sviluppi clinici, strategici e di finanziamento recenti, inclusa un ulteriore investimento strategico e l'espansione della collaborazione con Medtronic, una nuova relazione strategica di capitale con Ligand, un accordo di diritto di prelazione con Terumo, l'accelerazione dell'arruolamento nello studio pivot BACKBEAT di AVIM Therapy, e l'inizio dell'arruolamento dei pazienti nel Virtue SAB US pivotal IDE coronary trial.
Dettagli della conferenza: numero verde 877-407-9039; internazionale 201-689-8470; ID conferenza 13756518; webcast disponibile su https://viavid.webcasts.com/starthere.jsp?ei=1738644&tp_key=c80bc7995c.
Orchestra BioMed (Nasdaq: OBIO) realizará una llamada de actualización de negocio el miércoles 12 de noviembre de 2025 a las 8:00 AM ET. La empresa dijo que la llamada cubrirá desarrollos clínicos, estratégicos y de financiación recientes, incluida una inversión estratégica adicional y expansión de la colaboración con Medtronic, una nueva relación de capital estratégico con Ligand, un acuerdo de derecho de tanteo con Terumo, aceleración de la inscripción en el estudio pivotal BACKBEAT de AVIM Therapy, e inicio de la inscripción de pacientes en el ensayo IDE coronario pivotal de Virtue SAB US.
Detalles de la conferencia: Llamada gratuita 877-407-9039; internacional 201-689-8470; ID de conferencia 13756518; webcast disponible en https://viavid.webcasts.com/starthere.jsp?ei=1738644&tp_key=c80bc7995c.
Orchestra BioMed (Nasdaq: OBIO)은 2025년 11월 12일 수요일 오전 8:00(동부표준시)에 비즈니스 업데이트 콜을 주최합니다. 회사는 이번 콜에서 최근 임상, 전략 및 재무 개발을 다룰 것이며, Medtronic과의 추가 전략적 투자 및 협력 확장, Ligand와의 새로운 전략적 자본 관계, Terumo와의 우선협상권 계약, AVIM Therapy의 BACKBEAT 임상 연구의 등록 가속화, 및 Virtue SAB US pivotal IDE coronary trial의 환자 등록 시작을 포함합니다.
컨퍼런스 세부 정보: Toll Free 877-407-9039; International 201-689-8470; Conference ID 13756518; webcast는 https://viavid.webcasts.com/starthere.jsp?ei=1738644&tp_key=c80bc7995c에서 이용 가능합니다.
Orchestra BioMed (Nasdaq: OBIO) organisera un appel de mise à jour commerciale le mercredi 12 novembre 2025 à 8h00 ET. La société a déclaré que l'appel couvrira les développements cliniques, stratégiques et financiers récents, y compris un investissement stratégique supplémentaire et l'expansion de la collaboration avec Medtronic, une nouvelle relation de capital stratégique avec Ligand, un accord de droit de premier refus avec Terumo, l'accélération de l'enrôlement dans l'étude pivot BACKBEAT d'AVIM Therapy, et le démarrage de l'enrôlement des patients dans l'essai IDE coronarien pivot Virtue SAB US.
Détails de la conférence : Téléphone sans frais 877-407-9039; international 201-689-8470; ID de la conférence 13756518; webcast disponible sur https://viavid.webcasts.com/starthere.jsp?ei=1738644&tp_key=c80bc7995c.
Orchestra BioMed (Nasdaq: OBIO) wird am Mittwoch, dem 12. November 2025 um 8:00 Uhr ET einen Geschäft-Update-Anruf abhalten. Das Unternehmen sagte, dass der Anruf neueste klinische, strategische und finanzielle Entwicklungen beinhalten wird, einschließlich einer zusätzlichen strategischen Investition und Erweiterung der Zusammenarbeit mit Medtronic, einer neuen strategischen Kapitalbeziehung mit Ligand, einer Right of First Refusal-Vereinbarung mit Terumo, der Beschleunigung der Einschreibung in die BACKBEAT-pivotal-Studie von AVIM Therapy, und der Aufnahme der Patienteneinschreibung in die Virtue SAB US pivotal IDE coronary trial.
Konferenzdetails: Kostenfreier Anruf 877-407-9039; International 201-689-8470; Conference ID 13756518; Webcast verfügbar unter https://viavid.webcasts.com/starthere.jsp?ei=1738644&tp_key=c80bc7995c.
Orchestra BioMed (Nasdaq: OBIO) ستعقد مكالمة تحديث أعمال في الأربعاء 12 نوفمبر 2025 الساعة 8:00 صباحاً بتوقيت شرق الولايات المتحدة. قالت الشركة إن المكالمة ستغطي التطورات السريرية والاستراتيجية والمالية الأخيرة، بما في ذلك استثمار استراتيجي إضافي وتوسع التعاون مع Medtronic، وعلاقة رأس مال استراتيجي جديدة مع Ligand، واتفاق حق الرفض الأول مع Terumo، وتسريع التسجيل في دراسة BACKBEAT المحورية لـ AVIM Therapy، وبدء تسجيل المرضى في تجربة IDE التاجية المحورية Virtue SAB US pivotal.
تفاصيل المؤتمر: الاتصال المجاني 877-407-9039؛ الدولي 201-689-8470؛ معرف المؤتمر 13756518؛ البث المباشر متاح على https://viavid.webcasts.com/starthere.jsp?ei=1738644&tp_key=c80bc7995c.
- None.
- None.
NEW HOPE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will host a business update call on Wednesday, November 12th at 8:00 AM ET.
The business update will focus on recent significant clinical, strategic and financing developments, including the Company’s additional strategic investment from and collaboration expansion with Medtronic, its new strategic capital relationship with Ligand, its new right of first refusal agreement with Terumo, acceleration of enrollment in the BACKBEAT pivotal study of AVIM Therapy, the initiation of patient enrollment in the Virtue SAB US pivotal IDE coronary trial.
Conference Call Details
Wednesday, November 12, at 8:00 AM Eastern Time
Toll Free: 877-407-9039
International: 201-689-8470
Conference ID: 13756518
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1738644&tp_key=c80bc7995c
About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered as a firmware upgrade to a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic (NYSE: MDT), one of the largest medical device companies in the world, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designation for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind drug delivery angioplasty balloon system designed to deliver a proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary ISR, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.
Investor Contact:
Silas Newcomb
Orchestra BioMed
Snewcomb@orchestrabiomed.com
Media Contact:
Kelsey Kirk-Ellis
Orchestra BioMed
kkirkellis@orchestrabiomed.com
FAQ
When is Orchestra BioMed (OBIO) hosting its business update call in November 2025?
How can investors join the Orchestra BioMed (OBIO) conference call on November 12, 2025?
What clinical updates will Orchestra BioMed (OBIO) discuss on the November 12, 2025 call?
What strategic partnerships will Orchestra BioMed (OBIO) highlight on the November 12, 2025 call?
Where can I watch the Orchestra BioMed (OBIO) November 12, 2025 webcast?
